Cresco Labs Reports Q3 2026 Financial Results

CHICAGO – Cresco Labs Inc. announced third-quarter net revenue of $173 million, a 5% increase from the $165 million recorded during the same period last year and roughly unchanged from the second quarter. Retail sales contributed $121 million to overall revenue, while wholesale channels generated $52 million.

Profitability metrics reflected operational adjustments and integration costs. Cresco posted a gross profit of $79 million, with adjusted gross profit reaching $81 million, or 46.8% of revenue. Adjusted EBITDA totaled $35 million, representing an adjusted margin of 20.2%. On a GAAP basis, the operator logged a net loss of $15 million, influenced by debt service and non-recurring expenses tied to corporate development and federal regulatory positioning.

Operating cash generation remained a central highlight of the quarter. Cresco generated $26 million in operating cash flow, up from $15 million in Q2 2026. Free cash flow reached $21 million after accounting for capital expenditures of $5 million, which went toward production upgrades in Ohio and Massachusetts alongside new retail construction. The company concluded September with $76 million in total cash and cash equivalents against $454 million in long-term debt.

Operational growth centered on geographic density. Cresco closed acquisition of nine Pennsylvania storefronts, bringing its Sunnyside network in the Commonwealth to 27 locations – the largest single retail footprint in that market. The company also finalized its eight-store buildout in Ohio to capture expanding adult-use volume, and opened its first medical dispensary in Prestonsburg, KY. In its home state of Illinois, management maintained category leads in flower, concentrates, and edibles, opting to protect wholesale price-per-gram averages rather than discounting to chase commoditized vape volumes.

For the fourth quarter, executives anticipate revenue to decline in the low single digits sequentially, standard for seasonal fourth-quarter purchase patterns, before higher-cost inventory clears and newer retail assets reach full productivity.

Cresco Labs continues to execute a disciplined capital strategy that emphasizes balance sheet preservation over unfocused geographic reach. Converting over 60% of adjusted EBITDA into free cash flow reflects strict cost control and effective working capital management. By deepening its retail presence in Pennsylvania and Ohio while establishing early operational roots in Kentucky, the company is building structural leverage in markets with durable demand. Federal reforms and capital-market uplisting timelines will dictate broader sector valuations, but Cresco’s core operational machine is generating real liquidity today.